Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
The Oncologist|October 10, 2019
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced CancerMargaret E Gatti-Mays, Jason M Redman, Renee N Donahue, et al.
Biorxiv : the Preprint Server for Biology|August 8, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionFen Ma, Sen Chen, Luigi Cecchi, et al.
The Oncologist|January 11, 2026
The Quadruple Immunotherapy for Colorectal Cancer (QuICC) Trial for Mismatch Repair-Proficient Metastatic Colorectal CancerDara Bracken-Clarke, Danielle M Pastor, Jennifer L Marté, et al.
The Journal of Clinical Investigation|December 1, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionFen Ma, Sen Chen, Luigi Cecchi, et al.
The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancerPeter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerHoussein Abdul Sater, Jennifer L Marté, Renee N Donahue, et al.
JCO Precision Oncology|September 19, 2019
Low Abundance of Circulating Tumor DNA in Localized Prostate CancerS Thomas Hennigan, Shana Y Trostel, Nicholas T Terrigino, et al.
Cancer Research|January 13, 2026
MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate CancerSurendra Gulla, Tej Sharma, Ephraim Gardner, et al.
Journal for Immunotherapy of Cancer|March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancerRavi A Madan, Fatima Karzai, Renee N Donahue, et al.
Pageof 7